GPR56 antibody (PE)

Catalog No. ABIN2662736

The Mouse Monoclonal anti-GPR56 antibody has been validated for FACS and CyTOF. It is suitable to detect GPR56 in samples from Human.

Quick Overview for GPR56 antibody (PE) (ABIN2662736)

Target: GPR56 (G Protein-Coupled Receptor 56 (GPR56))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This GPR56 antibody is conjugated to PE

Application: Flow Cytometry (FACS), Cytometry by Time of Flight (CyTOF)

Clone: CG4

Product Details anti-GPR56 Antibody (PE)

Purification: The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for GPR56

Target: GPR56 (G Protein-Coupled Receptor 56 (GPR56))

Alternative Name: GPR56

Background: GPR56, also known as TM7XN1, is an orphan G-protein-coupled receptor (GPCR) containing seven transmembrane domains and a mucin-like domain in the N-terminal region. The total length of the human GPR56 gene is approximately 15 kb, and it consists of 13 exons and encodes 693 amino acids. GPR56 is expressed in a wide range of tissues, such as brain, thyroid gland, and heart. Mutations in human GPR56 gene were found to cause a specific brain malformation called bilateral frontoparietal polymicrogyria. Recently, GPR56 was found specifically expressed on cytotoxic NK and T lymphocytes, including CD8+, CD4+, and γδ T cells, which might affect the migratory properties of these cells. GPR56 was also found significantly downregulated in some cancer cells, suggesting that it may play a role in growth suppression and cancer metastasis.